CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 30 target
Drug / intervention
CAR T cellsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05089266
NCT05089266Phase 1Unknown
CompareCT.gov

Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors.

Shanghai Cell Therapy Group Co.,Ltd·interventional·Posted Oct 22, 2021·Updated Jul 17, 2023

In Brief

A Phase 1 clinical trial evaluating CAR T cells for Colorectal Cancer. Targeting 30 participants across 1 site.

Detailed Summary

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesChina
Collaborators--

Timeline

Phase 1UnknownOverdue
20222023202420252026
First PostedOct 22, 2021
Enrollment StartNov 30, 2021
Primary CompletionJul 30, 2024
Study CompletionJan 30, 2025
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 4.7 years ago

Interventions

CAR T cellsdrug

αPD1-MSLN-CAR T Cells